Cipla Q2 Profit Seen Up 17%; Export Formulations Business May Grow Around 10%

Pharma firm Cipla's second quarter profit is likely to increase 17 percent to Rs 414.7 crore compared with Rs 354.3 crore in year-ago.

Revenue during the quarter is seen rising 7 percent to Rs 4,008.8 crore from Rs 3,751 crore YoY, according to average of estimates of analysts polled by CNBC-TV18.

Revenue growth may be driven by recovery in India & Invagen portfolio in US. Export formulations business is likely to grow around 10 percent YoY.

For more information Call us ✆ +91 9111-179961 or Visit Dollar Advisory